New Diabetes Drug Shown To Be Effective in High Risk Patients
A Johnson & Johnson treatment, while tentative, has shown great promise in reducing blood glucose levels in diabetic patients. The drug, known as canagliflozin, has been determined to be a meaningful effective drug in weight loss and blood pressure; but now it has shown to be a particularly dutiful drug in diabetes cases, specifically diabetes type 2.
“It’s always a challenge to try and reduce weight, reduce blood glucose, reduce blood pressure, and here you’ve got an agent which will help you to reduce weight, blood sugar, and blood pressure all in one go,” David Matthews, a lead researcher from the study, stated about the results from the experimental study.
Data was collected from greater than 1,700 patients and proved to be a phenomenal breakthrough in the field of medical science and diabetes treatments. If the drug is accepted, it would diversify the current array of diabetes medications given the effectiveness. Patients that were a part of the study were noted to have had diabetes type 2 for a period of at least 16 years and had also taken other forms of medicines for treating their ailment. More than half of the patients had prior medical histories of other complications such as heart attacks and/or stroke. After a period of 18 weeks of treatment, there was a clinical sign within patients given canagliflozin of blood glucose stability. Patients who were given the drug experienced moderate increases in both LDL and HDL cholesterol levels. The increase in LDL, scientists determined was not automatically a cause for concern. Given that canagliflozin has also been shown to be effective in blood pressure, researchers also were able to receive more data from the study. “Blood pressure certainly comes down in significant amounts, in fact in amounts that you would regard to be quite respectable in an anti-hypertension agent,” Matthews added.
Given weight loss is also a prominent complication that results in diabetics, the drug has also been foreseen to be particularly attractive because of its effectiveness. Specifically, canagliflozin is in the family of a precise medical treatment medicine known as SGLT2 inhibitors, which work to block any form of reabsorption of sugar in the kidneys while forcing the body to increase glucose excretion in the urine. This, in turn, lowers blood glucose levels. There are always side effects with any medications and with prior studies on canagliflozin, researchers were not able to adequately determine many side effects, but did note that it was possible diabetics would exhibit lower blood pressure and an increase in urination.
Researchers were interested in understanding the particular complications that may result with the liver in patients that took the drug. “All in all, you’ve got no real safety signal coming out of the liver or the renal aspects (kidneys) that would give cause for concern. The results from this sub study suggest that canagliflozin could provide an important new treatment option for higher risk adult patient with type 2 diabetes,” Matthews continued in his speaking on the treatment study.
Due to the overwhelming helpfulness of the drug on type 2 diabetes, researchers are hopeful it may help individuals with type 1 diabetes also.
- What Diabetes Supplies Should You Purchase? 29.02.2016